Previous 10 | Next 10 |
Nanobiotix S.A. (NBTX) Q3 2022 Earnings Call Transcript November 10, 2022 08:00 AM ET Company Participants Kate Mcneil - Senior Vice President, Investor Relations Laurent Levy - Co-Founder & Chief Executive Officer Bart Van Rhijn - Chief Financial Officer ...
Data show that radiotherapy-activated NBTXR3 followed by anti-PD-1 was feasible and well tolerated in the complete dose escalation part of the Company’s phase 1 immunotherapy study with a recommended phase 2 dose established at 33% of gross tumor volume in all 3 cohorts Results...
Nanobiotix press release ( NASDAQ: NBTX ): Q3 Nanobiotix reported cash and cash equivalents totaling €53.5 million as of September 30, 2022, compared to €83.9 million as of December 31, 2021. In October 2022 Nanobiotix executed a final agreement with the Euro...
Established recommended Phase 2 dose (RP2D) for NBTXR3 plus anti-PD-1 in patients with locoregional recurrent and recurrent and/or metastatic head and neck cancer, lung metastases from any primary tumor, or liver metastases from any primary tumor Updated Phase 1 NBTXR3 plus anti-PD-1 ...
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Eur...
PARIS and CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for pat...
PARIS and Cambridge, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possib...
PARIS and CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibi...
French biotech Nanobiotix ( NASDAQ: NBTX ) on Tuesday said it had reached a final agreement with the European Investment Bank (EIB) to re-align about €30.7M in outstanding debt obligations with its expected development and commercialization timelines. The compan...
PARIS and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibi...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...